Baseline characteristics and demographics
| Characteristics | RA (N=7964) | PsA (N=783) | UC (N=1157) | PsO (N=3663) |
| Age, years | ||||
| Mean (SD) | 52.6 (12.1) | 48.7 (12.0) | 41.3 (13.9) | 44.8 (12.9) |
| Median (range) | 53.0 (18–86) | 50.0 (18–78) | 39.0 (18–81) | 45.0 (18–82) |
| <65 at baseline, n (%) | 6694 (84.1) | 711 (90.8) | 1080 (93.3) | 3443 (94.0) |
| ≥65 at baseline, n (%) | 1270 (15.9) | 72 (9.2) | 77 (6.7) | 220 (6.0) |
| Female, n (%) | 6522 (81.9) | 428 (54.7) | 478 (41.3) | 1117 (30.5) |
| Region, n (%) | ||||
| Europe | 2180 (27.4) | 542 (69.2)* | 686 (59.3) | 1563 (42.7) |
| USA/Canada | 2021 (25.4) | 158 (20.2) | 241 (20.8) | 1559 (42.6) |
| Asia | 1775 (22.3)† | 15 (1.9) | 123 (10.6) | 185 (5.1) |
| Latin America | 1246 (15.6) | 68 (8.7) | NA | 356 (9.7) |
| Rest of the world | 742 (9.3) | NA | 107 (9.2) | NA |
| BMI (kg/m2), mean (range) | 27.1 (12.1–70.8) | 29.6 (17.0–54.6) | 24.8 (15.8–55.0) | 29.9 (15.4–64.8) |
| BMI ≥30 kg/m2, n (%) | 2138 (26.8) | 333 (42.5) | 159 (13.8) | 1544 (42.2) |
| Disease duration (years), mean (range) | 8.1 (0.0–65.7) | 7.7 (0.2–43.4) | 8.2 (0.4–42.5) | 18.3 (0.6–68.1) |
| CRP (mg/L), median (Q1–Q3) | 9.2 (3.8–22.8) | 4.8 (1.7–12.6) | 4.5 (1.7–11.5) | 2.7 (1.1–6.5) |
| Smoking status, n (%) | ||||
| Never smoked | 4996 (62.7) | 485 (61.9) | 740 (64.0) | 1412 (38.5) |
| Smoker | 1366 (17.2) | 140 (17.9) | 59 (5.1) | 1380 (37.7) |
| Ex-smoker | 1388 (17.4) | 158 (20.2) | 357 (30.9) | 871 (23.8) |
| Unknown | 214 (2.7) | 0 (0.0) | 1 (0.1) | 0 (0.0) |
| Prior therapy, n (%) | ||||
| Methotrexate | 6657 (83.6) | 725 (92.6) | NA | 1157 (31.6) |
| Non-bDMARD (non-methotrexate) | 3739 (46.9) | 372 (47.5) | NA | 390 (10.6) |
| Thiopurines | NA | NA | 823 (73.2) | NA |
| TNFi | 1245 (15.6) | 377 (48.1) | 612 (54.4) | 580 (15.8) |
| Non-TNFi bDMARD | 414 (5.2) | 46 (5.9) | NA | 214 (5.8) |
| Concomitant medications | ||||
| Corticosteroids, n (%) | 4254 (53.4) | 171 (21.8) | 523 (45.2) | NA‡ |
| Corticosteroids dose (mg/day), mean (range) | 6.5 (0.01–200.0) | 1.4 (0.0–20.0) | 16.0 (2.0–30.0) | NA‡ |
*Also includes Australia and Russia.
†East/South Asia.
‡Concomitant corticosteroid use was not permitted in the PsO studies.
bDMARD, biologic disease-modifying antirheumatic drug; BMI, body mass index; CRP, C-reactive protein; N, number of patients in the disease cohort (note that N varies for some variables); n, number of patients with each characteristic; NA, not applicable; PsA, psoriatic arthritis; PsO, psoriasis; Q, Quarter; RA, rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor; UC, ulcerative colitis.